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Abstract
Background: The effect of sevoflurane on the doxorubicin-induced myocardial injury was explored by 
investigating the phosphorylation states of proteins in phosphatidylinositol 3-kinase (PI3K)/Akt/mam-
malian target of rapamycin (mTOR) signaling pathway.
Methods: Myocardial injury rat models were induced by doxorubicin and evenly assigned into five 
groups according to different treatment: Doxorubicin group (DG, 200-µL saline solution), sevoflurane 
group (SevG, inhaled with 2.4% sevoflurane for 2 h), LY294002 group (LYG, Akt inhibitor, 0.3 mg/kg 
in 200-µL Dimethyl Sulfoxide [DMSO]), solvent DMSO control group (SG) and autophagy inhibitor 
3-methyladenine (3-MA) group (MG, 30 mg/kg in 200-µL DMSO). The healthy rats were assigned to 
a contro1 group (CG, 200-µL saline solution). Myocardial apoptosis was detected by terminal deoxy-
nucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The concentration of cardiac troponin I  
(cTnI) was detected by ELISA. The levels of total Akt (t-Akt), phosphorylated Akt (p-Akt), mammalian 
target of rapamycin (mTOR), phosphorylated-mTOR (p-mTOR) and autophagy marker LC3-II was 
detected by Western Blot. The experiments were also repeated at the cell level.
Results: Terminal deoxynucleotidyl transferase dUTP nick end labeling analysis showed that the ap-
optosis rates were high in DG and SG, reached the highest level in LYG, reduced in SevG and MG, and 
reached the lowest level in CG. The levels of p-Akt p-mTOR were low in groups DG and SG, reached 
the lowest level in LYG, increased in SevG and MG, and reached the highest level in CG. In contrast, 
LC3-II expression, apoptosis index and serum cTnI concentration were high in DG and SG, reached 
the highest level in LYG, reduced in SevG and MG, and reached the lowest level in CG (p < 0.05). Cell 
experiment showed similar results as with animal experiments. 
Conclusions: Sevoflurane ameliorates myocardial injury by affecting the phosphorylation states of the 
proteins in PI3K/Akt/mTOR signaling pathway and reducing the injury biomarker. (Cardiol J 2017; 
24, 4: 409–418)
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Introduction
Chronic heart failure is a serious threat to 
public health and can be caused by many heart 
disorders, such as myocardial infarction, chronic 
hypertension and toxic agents. The anthracycline 
doxorubicin (DOX) is widely used for tumor ther-
apy, but its wide use often leads to heart failure [1]. 
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Many approaches are implemented to protect the 
heart against DOX-induced cardiac injury, but the 
problems remain unresolved.
Anesthetic sevoflurane has been widely used 
clinically and it has the lowest solubility,  allowing 
rapid induction and recovery. Sevoflurane shows 
better protective functions for cardiac injury. On the 
other hand, phosphatidylinositol 3-kinase (PI3K) 
has been reported to be involved in myocardial func-
tion, such as contractility. A previous study showed 
that myocardial dysfunction was controlled when 
phosphatidylinositol 3-kinase (PI3K) was inhibited 
in the rat model with a decrease in the phospho-
rylation of myocardial phospholamban [2]. Serine/ 
/threonine protein kinase Akt can be activated by 
various extracellular stimuli in a PI3K-dependent 
manner and regulates many functions such as car-
diac survival, growth and metabolism. Akt signaling 
pathway plays an important role in cardiac growth, 
contractile function, and coronary angiogenesis [3]. 
A previous study demonstrated that sevoflurane 
reduced DOX-induced rat cardiac injury [4]. Thus, 
sevoflurane improves DOX-induced cardiac injury 
perhaps by affecting Akt signaling pathway. 
Doxorubicin can induce cardiomyocytes apop-
tosis and shows obvious cardiac toxicity [5]. DOX-
-induced myocardial toxicity which may involved 
in many complications, such as energy metabolism, 
free radical injury, calcium overload and apoptosis 
factors, all of which result in myocardial injury. Fur-
thermore, DOX has been found to be associated with 
the changes of cellular autophagy [6], which is also 
involved in the pathogenesis of myocardial injury [7]. 
Light chain 3 (LC3)-II [8], mTOR [8] and Akt [8] are 
important autophagy markers. It has been confirmed 
that sevoflurane reduces myocardial injury by inhib-
iting autophagy and activating PI3K/Akt signaling 
pathway [9]. Furthermore, phosphorylation at Anti-p 
(Ser473) of Akt, along with Thr308 of its activation 
loop, is critical for Akt function. Akt-Ser473 phospho-
rylation is required for rictor-mTOR (TORC2) [10]. 
A previous study showed that Akt phosphorylation 
inhibited the apoptosis of endothelial cells. Activation 
of the serine/threonine kinase Akt contributed to 
the changes in endothelial morphology and function 
[11]. Phosphorylated-Akt has been shown to be as-
sociated with phosphorylated-mTOR in most ovarian 
tumors with an evaluated phosphorylation level [12]. 
Results suggest that the phosphorylation states of 
proteins are important for the activity of PI3K/Akt/ 
/mTOR signaling pathway. Cardiac troponin I (cTnI), 
a biomarker for the diagnosis of acute myocardial 
infarction, is also associated with cardiac injury [13]. 
Therefore, it was hypothesized that sevoflurane 
treatment ameliorates cardiac injury and may affect 
the phosphorylation states of proteins of PI3K/Akt/ 
/mTOR pathway and related important molecules.
Methods
Myocardial cells H9c2 were purchased from 
Cell Bank of Shanghai Institute of Cell Biology, 
Chinese Academy of Sciences (Shanghai, China). 
A total of 36 Sprague-Dawley rats (8 weeks, weight 
200–250 g) were purchased from the Animal Center 
of Wenzhou Medical University (Wenzhou, China). 
Anti-p-Akt (Ser473) antibody (4060), Anti-p-mTOR 
antibody (5536) and Anti-mTOR antibody (2972) 
were purchased from Cell Signaling Company 
(Danvers, MA, USA). Anti-LC3 antibody (L7543), 
anti-glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) antibody, LY294002 (a potent inhibitor 
of numerous proteins with morphine-containing 
chemical compound) and 3-methyladenine (3-MA) 
were purchased from Sigma (St. Louis, MO, USA). 
Establishment of myocardial injury model
Before the experiment, all protocols were 
approved by the Animal Ethical Committee of 
Wenzhou Medical College (Wenzhou, China). Ac-
cording to a previous report [14], 30 rats were 
intraperitoneally injected with DOX at 4 mg/kg in 
200-µL saline solution weekly for 6 weeks. Mean-
while, the 6 healthy rats were intraperitoneally 
injected with 200-µL saline solution as a control 
group. Myocardial injury model was confirmed 
by rat growth, the ratio of heart weight and body 
weight, electrocardiograms (ECGs) analysis and 
the TUNE analysis for myocardial tissues. The 
cardiac marker lactate dehydrogenase (LDH) was 
measured by using Lactate Dehydrogenase Assay 
Kit from Sigma (MAK066). Creatine kinase-MB 
(CK-MB) was detected by using Creatine Kinase 
Activity Assay Kit from Sigma (MAK116).
Grouping
Myocardial injury rat models were induced 
by DOX and randomly divided into five groups 
according to different treatment: Doxorubicin 
group (DG, 200-µL saline solution), sevoflurane 
group (SevG), LY294002 group (Akt inhibitor, 
LYG), Solvent DMSO group (SG) and autophagy 
inhibitor 3-methyladenine (3-MA) group (MG). 
Meanwhile, the healthy rats were assigned as 
a control group (CG, 200-µL saline solution) (Fig. 1). 
In groups CG and DG, the rats were mechanically 
ventilated for 2 h. In SevG, the rats were inhaled 
with 2.4% sevoflurane for 2 h. In LYG, the rats 
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were intraperitoneally injected with LY294002 
0.3 mg/kg injection in 200-µL Dimethyl Sulfoxide 
(DMSO). In SG, the rats were intraperitoneally 
injected with 200-µL DMSO. In MG, the rats were 
intraperitoneally injected with 30 mg/kg 3-MA in 
200-µL DMSO. 
Cell experiments
The myocardial cells H9C2 were cultured in 
high glucose Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% fetal bovine serum at 
37° in 5% CO2 incubator. Cardiomyocytes were 
adjusted to 105/mL and seeded in 6-well (2 mL/well) 
culture plate. Doxorubicin was added to each cell 
at a final concentration of 2 μM and treated for 2 h. 
With the animal experiment, all the cells were as-
signed to six groups (n = 6 for each group) accord-
ing to different treatment: CG, DG, SevG, LYG, SG 
and MG) (Fig. 1). In CG, the cells were not treated 
by DOX. In DG, 1 mL cells were incubated with 
4 µg/mL for 2 h. In LYG, 1 mL cells were treated 
LY294002 with a final concentration of 20 μM in 
1-µL DMSO. In SevG, the cells were treated 2.4% 
sevoflurane for 2 h. In SG, 1 mL cells were treated 
with 1-µL DMSO for 2 h. In MG, 1 mL cells were 
treated with 3-MA at a final concentration of 5 mM 
in 1-µL DMSO. All the following experiments were 
performed at cellular level.
TUNEL analysis for cardiac  
myocyte apoptosis
Apoptotic cells were identified by the TUNEL 
assay and quantitated under a microscope by 
a single observer. Cell number was counted under 
Figure 1. The flowchart of present study. Myocardial injury rat models were induced by doxorubicin and randomly 
divided into five groups according to different treatments: Doxorubicin group (DG), sevoflurane group (SevG), 
LY294002 group (Akt inhibitor, LYG), Solvent DMSO control group (SG) and autophagy inhibitor 3-methyladenine 
(3-MA) group (MG). Meanwhile, the healthy rats were assigned as a control group (CG). In SevG, the rats were inhaled 
with 2.4% sevoflurane for 2 h. In LYG, the rats were intraperitoneally injected with LY294002 0.3 mg/kg injection in 
200-µL DMSO. In SG, the rats were intraperitoneally injected with the equal volume of DMSO. In MG, the rats were 
intraperitoneally injected with 3-MA at 30 mg/kg.
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a high-power from six different views. Promyelo-
cytic leukemia oncogenic domain (POD) apoptosis 
detection kit (Roche, USA) was used to detect 
apoptotic cells. 
Enzyme-linked immunosorbent  
assay (ELISA) analysis
Cardiac troponin I concentration were ana-
lyzed in myocardial tissue or cultured cells by 
using an Rat Cardiac Troponin I ELISA Kit Life 
from Diagnostics, Inc. (Cat. No. CTNI-2-HS, West 
Chester, PA, USA).
Western Blot analysis 
The myocardial tissue (500 mg) was excised 
from the experimental rats and the protein levels 
of P-Akt, Akt, P-mTOR, mTOR and LC3-II were 
analyzed by Western Blot. Myocardial tissue was 
grounded with a pellet pestle rinder (Kontes Glass, 
Vineland, NJ, USA) for 3 min. The isolated cells 
were collected by rapid filtration onto glass fiber 
filters. The cells were treated with a proteinase in-
hibitor cocktail, 2 mM N-ethylmaleimide, 2 mg/mL 
aprotinin, 4 mg/mL pepstatin, ten mg/mL leu-
peptin, and 2 mM phenylmethylsulphonyl fluoride, 
and lysed by 3-cycle freezing (10 min) and thawing 
(5 min). The supernatant samples (or supernatants 
of cultured cells) were collected by centrifuge and 
solubilized in the buffer with 50 mM Tris HCl, 10% 
glycerol, 1% SDS, 0.05% bromophenol blue, and 
5% b-mercaptoethanol and the pH was adjusted 
to 6.8. 10-µg protein from each cell lysate were 
loaded onto 10% sodium dedecyl sulfate polyacryl-
amide gel electrophoresis and electrophoresed at 
200 V for 2 h. After electrophoresis, the separated 
proteins were transferred to a polyvinylidene 
fluoride (PVDF) membrane in transfer buffer 
(48 mmol/L Tris, 39 mmol/L glycine, 20% methanol, 
pH 9.2) for 2 h at a constant current of 20 amps 
and blocked in Tris buffered saline containing 2.5% 
non-fat dry milk for 30 min. The membranes were 
incubated with the antibodies (diluted 1:1000) to 
P-Akt, Akt, P-mTOR, mTOR and LC3-II overnight 
at 4°C. An avidin-biotin complex (ABC) peroxidase 
and substrate kit was used to detect the primary 
antibodies bound to the antigen. With X-ray film 
exposure and photograph, the expression of P-Akt, 
Akt, P-mTOR, mTOR and LC3-II was measured 
using Quantity One software with the internal 
control of b-actin.
Statistical analysis
Student’s t test was used to compare the levels 
of weight loss, LDH, CK-MB, P-Akt, Akt, P-mTOR, 
mTOR and LC3-II between 2 different samples (via 
a CG group or a DG group). Statistical analysis was 
conducted in the in vitro experiments by using the 
independent two-tailed t-test. Statistical analysis 
was performed with the SPSS 20.0.The p value 
was regarded as significant if it was less than 0.05.
Results
Evaluation of myocardial injury model 
During the experiment, healthy rat weight 
was gained and there were no deaths. In contrast, 
model rats reduced their activities resulting in 
reduced weight, 3 rats had ascites (each one 
from DG, SevG and MG, respectively) and 4 rats 
died (1 from DG, 2 from LYG and 1 from SG). 
The number was too low to be analyzed by using 
a statistical method. These rats were removed 
from the final statistical analysis. Thus, there were 
6, 4, 5, 4, 5, 6 cases in CG, DG, SevG, LYG, SG and 
MG groups finally, respectively. The mean body 
weight of model animals was significantly reduced 
in all models when compared with healthy ones 
(p < 0.05, Table 1). In contrast, the heart weight to 
body weight were increased significantly in model 
animals when compared with healthy controls 
(p < 0.05, Table 1). Comparatively, the activities of 
LDH and CK-MB were significantly increased in all 
models when compared with the healthy animals 
(p < 0.05, Table 2). ECG analysis also showed that 
model rats had significant ST-segment elevation 
when compared to controls (p < 0.05). All results 
suggest the myocardial injury model was success-
fully established.
Table 1. The comparison of body weight and heart weight between healthy rats and model rats after 
6-week doxorubicin treatment.
Groups Body weight [g] Heart weight [g] Heart weight/Body weight [mg/g]
CG 238.12 ± 29.25 0.75 ± 0.07 2.96 ± 0.34
DG 199.37 ± 28.48* 0.76 ± 0.09 3.68 ± 0.46*
 *p < 0.05 via a CG group; CG — healthy rats; DG — doxorubicin-induced myocardial injury rats
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Sevoflurane reduced the activities  
of LDH and CK-MB induced by DOX
Table 2 showed that DOX increased the ac-
tivities of LDH and CK-MB when compared with 
healthy rats (p < 0.05). There was no significant 
difference between DG and SG (p > 0.05), sug-
gesting DMSO did not affect the activity of LDH 
and CK-MB. In contrast, sevoflurane and 3-MA 
reduced the activities of LDH and CK-MB when 
compared with those from DG and SG (p < 0.05). 
All the results suggest that sevoflurane treatment 
is beneficial to reduce the activities of LDH and 
CK-MB in myocardial injury models.
TUNEL assay of cellular apoptosis 
TUNEL analysis showed that the damaged 
DNA was stained brown. In CG, no obvious apop-
totic cells were found. Compared with CG, cellular 
apoptosis was increased in DG and SG, and reached 
the highest level in LYG while the apoptosis was 
reduced in SevG and MG (p < 0.05) (Fig. 2). The 
apoptosis indexes showed a similar trend at the 
cell level (p < 0.05) (Tables 3, 4).
Protein concentration of cTnI  
and apoptosis index
For an animal experiment, serum concentra-
tion of cTnI was the lowest in CG among all groups. 
The level was increased in DG and SG, and reached 
the highest level in LYG while the levels were 
reduced in SevG and MG (p < 0.05) (Table 3). 
The apoptosis indexes showed the similar trend 
at the cell level (p < 0.05) (Table 3). In cellular 
experiments, the concentration of cTnI showed 
similar results with those of animal experiments. 
The concentration of cTnI was the lowest in CG 
Table 2. The effect of sevoflurane on creatine 
kinase-MB and lactate dehydrogenase (LDH)  
activities in doxorubicin-induced myocardial  
injury models.
Groups CK-MB [IU/L] LDH [IU/L]
CG 9124.73 ± 1367.16# 1955.26 ± 178.36#
DG 24652.55 ± 2671.65* 3638.23 ± 216.45*
SevG 16248.31 ± 2281.49*,# 2578.51 ± 198.32*,#
LYG 28954.35 ± 2956.74*,# 3942.53 ± 248.37*,#
SG 25002.71 ± 2544.23* 3679.39 ± 224.16*
MG 12169.23 ± 1865.44*,# 2219.47 ± 196.53*,#
Myocardial injury rat models were induced by doxorubicin and ran-
domly divided into five groups according to different treatments: 
Doxorubicin group (DG), sevoflurane group (SevG), LY294002 
group (Akt inhibitor, LYG), Solvent DMSO control group (SG) and 
autophagy inhibitor 3-methyladenine (3-MA) group (MG). Mean-
while, the healthy rats were assigned as a control group (CG). In 
SevG, the rats were inhaled with 2.4% sevoflurane for 2 h. In LYG, 
the rats were intraperitoneally injected with LY294002 0.3 mg/kg 
injection in 200-µL DMSO. In SG, the rats were intraperitoneally 
injected with 200-µL DMSO. In MG, the rats were intraperitoneally 
injected with 30 mg/kg 3-MA in 200-µL DMSO.*p < 0.05 via a CG 
group and #p < 0.05 via a DG group
Figure 2. TUNEL analysis for myocardial cell apoptosis (400 ×). Myocardial injury rat models were induced by doxo-
rubicin and randomly divided into 5 groups according to different treatments: Doxorubicin group (DG), sevoflurane 
group (SevG), LY294002 group (Akt inhibitor, LYG), Solvent DMSO control group (SG) and autophagy inhibitor 3-meth-
yladenine (3-MA) group (MG). Meanwhile, the healthy rats were assigned as a contro1 group (CG). In SevG, the rats 
were inhaled with 2.4% sevoflurane for 2 h. In LYG, the rats were intraperitoneally injected with LY294002 0.3 mg/kg 
injection in 200-µL DMSO. In SG, the rats were intraperitoneally injected with 200-µL DMSO. In MG, the rats were 
intraperitoneally injected with mg/kg 3-MA in 200-µL DMSO. 1 bar = 10 um.
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among all groups. The level was increased in DG 
and SG, reaching the highest level in LYG while the 
levels were reduced in SevG and MG (p < 0.05) 
(Table 4). The apoptosis indexes showed a similar 
trend at cell level as with the animal level (p < 0.05) 
(Tables 3 and 4).
p-Akt, p-mTOR and LC3-II levels
For an animal experiment, the levels of p-Akt, 
p-mTOR were the highest in CG among all groups 
(p < 0.05) (Fig. 3). The level was reduced in DG 
and SG and reached the lowest point in LYG while 
the levels were increased again in SevG and MG 
(p < 0.05) (Fig. 3). Comparatively, the concentra-
tion of Akt and mTOR did not change significantly 
(p > 0.05). In contrast, the concentration of LC3-II 
showed the reverse changing trends among all 
groups. The level of LC3-II was lowest in CG 
among all groups (p < 0.05) (Fig. 3). The level was 
increased in DG and SG and reached the highest 
point in LYG while the levels were reduced again 
in SevG and MG (p < 0.05) (Fig. 3). 
In the cellular experiment, similar results 
were also obtained. The levels of p-Akt, p-mTOR 
were highest in CG, among all groups (p < 0.05) 
(Fig. 4). The level was reduced in DG and SG 
reaching the lowest point in LYG while the levels 
were increased again in SevG and MG (p < 0.05) 
(Fig. 4). Comparatively, the concentration of Akt 
and mTOR did not change significantly (p > 0.05). 
In contrast, the concentration of LC3-II showed 
the reverse changing trend among all groups. The 
level of LC3-II was lowest in CG among all groups 
(p < 0.05) (Fig. 4). The level was increased in DG 
and SG, reaching the highest point in LYG while 
the levels were reduced again in SevG and MG 
(p < 0.05) (Fig. 4).
Discussion
In this study, a rat model of DOX-induced myo-
cardial injury was established with higher activities 
of LDH and CK-MB when compared with healthy 
rats (Table 2). Myocardial apoptosis was increased 
with the higher level of serum cTnI in a rat model 
when compared with a healthy rat (Table 3). Ren et 
al. [15] reported that 2-µM DOX can cause signifi-
cant cardiac myocyte apoptosis in vitro. Therefore, 
2-µM DOX was added to cell culture in the present 
study. Conzen et al. [16] reported that 2.4% sevo-
flurane showed obvious therapeutic results in a rat 
model and thus the same concentration was used 
here. LY294002 and 3-MA was also administered 
based on previous literature [17].
Autophagy is a lysosomal degradation process 
involved in intracellular degradation of unwanted 
macromolecules. However, excessive autophagy 
will cause cellular energy depletion and internal 
environment disorder. To start cellular autophagic 
pathways, cell death is called programmed cell 
death type II [18], which unlike apoptosis (pro-
grammed cell death type I). Doxorubicin increases 
energy metabolism, intracellular calcium overload, 
and can induce autophagy and cardiotoxicity. Res-
veratrol has been reported to control autophagy by 
inhibiting S6K1 (p70 S6 kinase1), so as to reduce 
Table 3. The concentration of cardiac troponin I 
(cTnI) vand apoptosis rate of myocardial tissues 
of animal model.
Groups cTnI [ng/mL] Apoptosis [%]
CG 0.21 ± 0.03# 7.71 ± 2.01#
DG 0.64 ± 0.04* 37.9 ± 2.82*
SevG 0.56 ± 0.03*,# 28.2 ± 1.24*,#
LYG 0.73 ± 0.05*,# 41.9 ± 2.12*,#
SG 0.60 ± 0.04* 39.3 ± 2.03*
MG 0.50 ± 0.02*,# 27.2 ± 1.82*
Myocardial injury rat models were induced by doxorubicin and ran-
domly divided into five groups according to different treatments: 
Doxorubicin group (DG), sevoflurane group (SevG), LY294002 
group (Akt inhibitor, LYG), Solvent DMSO control group (SG) and 
autophagy inhibitor 3-methyladenine (3-MA) group (MG). Mean-
while, the healthy rats were assigned as a control group (CG). In 
SevG, the rats were inhaled with 2.4% sevoflurane for 2 h. In LYG, 
the rats were intraperitoneally injected with LY294002 0.3 mg/kg 
injection in 200-µL DMSO. In SG, the rats were intraperitoneally 
injected with 200-µL DMSO. In MG, the rats were intraperitoneally 
injected with 30 mg/kg 3-MA in 200-µL DMSO.*p < 0.05 via a CG 
group and #p < 0.05 via a DG group
Table 4. The concentration of cardiac troponin I  
(cTnI) and apoptosis rate of myocardial cells H9C2. 
Groups cTnI [ng/mL] Apoptosis [%]
CG 0.24 ± 0.06# 7.28 ± 2.15#
DG 0.56 ± 0.07* 28.61 ± 2.24*
SevG 0.42 ± 0.04*,# 19.42 ± 1.82*,#
LYG 0.65 ± 0.07*,# 32.23 ± 2.61*,#
SG 0.57 ± 0.06* 27.12 ± 1.93*
MG 0.44 ± 0.05*,# 17.82 ± 2.03*,#
All the cells were divided into six groups (n = 6 for each group): 
control group (CG), Doxorubicin group (DG), sevoflurane group 
(SevG), LY294002 group (LYG), Solvent DMSO control group (SG) 
and 3-methyladenine (3-MA) group (MG). In CG, the cells were not 
treated by doxorubicin. In DG, the model cells were incubated for 
2 h. In LYG, all the cells were treated LY294002 at a final concentra-
tion of 20 µM. In SevG, the cells were treated 2.4% sevoflurane for 
2 h. In SG, 1-mL cells were treated with 1-µL DMSO for 2 h. In MG, 
1-mL cells were treated with 5 mM 3-MA in 1-µL DMSO. *p < 0.05 
via a CG group and #p < 0.05 via a DG group
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DOX-induced cardiac cell death [19]. Present find-
ings showed that the expression of LC3-II was 
increased in the model with DOX-induced cardiac 
injury and it significantly enhanced the level of 
serum cTnI, which suggests that autophagy activ-
ity was increased too. The application of autophagy 
inhibitor 3-MA reduced the levels of LC3-II and 
cTnI (Figs. 3, 4, Tables 3, 4) to inhibit autophagy, 
which implied that DOX reduced autophagy damage 
for cardiomyocytes.
Autophagy is regulated by autophagy-related 
genes (Atg), which comprises: Atg1 kinase com-
plex (Atg1-mAtg13-FIP200-Atg101), starts the 
activity of autophagy; PI3K kinase complex type III 
Figure 3. Western Blot analysis for the expression of Akt, p-Akt, mTOR, p-mTOR and cardiac troponin I in the rats with dif-
ferent treatment. Myocardial injury rat models were induced by doxorubicin and randomly divided into five groups ac-
cording to different treatments: Doxorubicin group (DG), sevoflurane group (SevG), LY294002 group (Akt inhibitor, LYG), 
Solvent DMSO control group (SG) and autophagy inhibitor 3-methyladenine (3-MA) group (MG). Meanwhile, the 
healthy rats were assigned as a control group (CG). In SevG, the rats were inhaled with 2.4% sevoflurane for 2 h. In LYG, 
the rats were intraperitoneally injected with LY294002 0.3 mg/kg injection in 200-µL DMSO. In SG, the rats were 
intraperi-toneally injected with 200-µL DMSO. In MG, the rats were intraperitoneally injected with 30 mg/kg 3-MA in 
200-µL DMSO. *p < 0.05 via a CG group and #p < 0.05 via a DG group; GAPDH — glyceraldehyde 3-phosphate dehy-
drogenase.
www.cardiologyjournal.org 415
Yini Wu et al., Sevoflurane ameliorates doxorubicin-induced myocardial injury
Figure 4. Western Blot analysis for the expression of Akt, p-Akt, mTOR, p-mTOR and cardiac troponin I in myocardial 
cells H9c2 with different treatment. All the cells were assigned into six groups according to different treatment: control 
group (CG), Doxorubicin group (DG), sevoflurane group (SevG), LY294002 group (LYG), Solvent DMSO control group 
(SG) and autophagy inhibitor 3-methyladenine (3-MA) group (MG). In CG, the cells were not treated by doxorubicin. 
In DG, the model cells were incubated for 2 h. In LYG, all the cells were treated LY294002 at a final concentration of 
20 µM. In SevG, the cells were treated 2.4% sevoflurane for 2 h. In SG, the cells were treated with equal volume of 
DMSO for 2 h. In MG, the cells were treated with 3-MA at a final concentration of 5 mM. *p < 0.05 via a CG group and 
#p < 0.05 via a DG group; GAPDH — glyceraldehyde 3-phosphate dehydrogenase.
(Vps34-PI3KIII-Becline1), promotes the forma-
tion of phagosome [20]. Doxorubicin can damage 
mitochondria, endoplasmic reticulum and leads to 
adenosine triphosphate production. Dysfunction 
of protein synthesis is often caused by myocar-
dial nutritional deprivation, which is also a typical 
cause of autophagy. In the process, the main target 
protein is involved in astrocyte-defined medium 
(ADM) regulation signaling pathway, which induces 
autophagy. Under normal circumstances, mTOR 
kinase complex binds Atg1, thereby inhibiting 
autophagy. When lack of nutrition is prominent, 
mTOR kinase will be dissociated with Atg1, and 
Atg1 is dephosphorylated. Therefore, Atg1 kinase 
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complex and autophagy is activated [21]. PI3K/Akt 
pathway is a major upstream regulator of mTOR 
signaling pathway, and PI3K/Akt/mTOR signaling 
pathway also regulates cell growth. Present findings 
showed that the levels of phosphorylated Akt and 
mTOR were highest in CG and lowest in DG and 
LYG while sevoflurane improved the phosphoryl-
ated states of Akt and mTOR in PI3K/Akt/mTOR 
signaling pathway (Fig. 3B, D, and Fig. 4B, D). Thus, 
sevoflurane may activate the activity of PI3K/Akt/ 
/mTOR signaling pathway by affecting the phospho-
rylated sates of main proteins in the pathway.
Clinical trials confirmed that sevoflurane had 
positive cardioprotective effect during bypass 
surgery of coronary artery [22]; Sevoflurane is 
an excellent adjuvant to propofol for protecting 
the heart in patients with coronary heart disease. 
A previous study found that sevoflurane might 
induce anti-apoptotic protein Bcl-2, inhibited Bax 
and Caspase [23] and reduced DOX-induced injury. 
Inamura et al. [24] demonstrated that sevoflurane 
treatment reduced ischemia-reperfusion apoptosis. 
Zhang et al. [25] reported sevoflurane treatment 
inhibited autophagy and reduced myocardial is-
chemia and reperfusion injury by affecting PI3K/ 
/Akt signaling pathway.
Present findings showed that sevoflurane 
treatment reduced cardiac injury by inhibiting the 
expression of LC3-II and increasing the level of 
phosphorylated protein p-Akt and p-mTOR (Figs. 
3, 4), which is closely associated PI3K/Akt/mTOR 
pathway. The results suggest that the decrease of 
p-Akt level promotes autophagy, resulting in myo-
cardial damage. Doxorubicin induced the inhibition 
of phosphorylation of Akt and mTOR. Further ap-
plication of PI3K inhibitor LY294002 also further 
inhibited the phosphorylation of Akt and mTOR, 
and increased the expression of LC3-II. Meanwhile, 
sevoflurane showed protective functions for myo-
cardial injury by activating the phosphorylation 
of PI3K/Akt/mTOR pathway and inhibiting the 
expression of cTnI.
Limitations of the study
There were some limitations for present work: 
1) The small sample size was the main limita-
tion of present study because the number of rats 
was restricted by the Animal Ethical Committee; 
2) the relationship between phosphorylated Akt 
and mTOR, and cardinal injury biomarker cTnI and 
or autophagy factor LC3-II was not confirmed, al-
though the changing trend was consistent; 3) 3 rats 
had ascites and 4 rats died. The number was too low 
to be analyzed by using a statistical method. These 
rats were removed from the final statistical analy-
sis. The reasons for those rats having ascites and 
dying can be complex. Two rats which died were 
from LYG, and thus DOX and LY294002 may have 
a synergistic function for causing myocardial injury. 
Cell death was reported when PI3K/Akt pathway 
was blocked by the PI3K inhibitor LY294002 [1]. 
The optimization is going to be performed in fu-
ture, including one-time dosage, interval time and 
accumulated dosages. 
Conclusions
In sum, sevoflurane treatment reduces myo-
cardial cell autophagy by affecting the phosphoryl-
ated sates of main proteins of PI3K/Akt/mTOR 
signaling pathway, and inhibiting the expression 
of cTnI. The exact mechanism of DOX-induced 
myocardial damage is not yet clear. The critical role 
of autophagy has been gradually recognized. Given 
the important role of phosphorylation of Akt and 
mTOR for myocardial injury, potential drugs should 
be developed for myocardial protection.
Acknowledgements
We are very grateful to all three anonymous 
reviewers for their critical and strategic comments, 
which has certainly improved the quality of pre-
sent paper. The work was supported by the Key 
projects of Zhejiang medical and health platform 
(No.2014ZDA031), the Lishui high level talent 
training project (No.2013RC04) and the Lishui Key 
Discipline Project (No.2014ZDxk06).
Conflict of interest: None declared
References
1. Prysyazhna O, Burgoyne JR, Scotcher J, et al. Phosphodiester-
ase 5 Inhibition Limits Doxorubicin-induced Heart Failure by 
Attenuating Protein Kinase G Ia Oxidation. J Biol Chem. 2016; 
291(33): 17427–17436, doi:  10.1074/jbc.M116.724070, indexed 
in Pubmed: 27342776.
2. Sato M, Yamanaka H, Iwasaki M, et al. Altered Phosphatidylino-
sitol 3-Kinase and Calcium Signaling in Cardiac Dysfunction 
After Brain Death in Rats. Ann Thorac Surg. 2016; 102(2): 
556–563, doi: 10.1016/j.athoracsur.2016.02.014, indexed in Pub-
med: 27130251.
3. Shiojima I, Walsh K. Regulation of cardiac growth and coronary 
angiogenesis by the Akt/PKB signaling pathway. Genes Dev. 
2006; 20(24): 3347–3365, doi: 10.1101/gad.1492806, indexed in 
Pubmed: 17182864.
4. Cao J, Xie H, Sun Y, et al. Sevoflurane post-conditioning reduces 
rat myocardial ischemia reperfusion injury through an increase 
in NOS and a decrease in phopshorylated NHE1 levels. Int 
J Mol Med. 2015; 36(6): 1529–1537, doi: 10.3892/ijmm.2015.2366, 
indexed in Pubmed: 26459736.
www.cardiologyjournal.org 417
Yini Wu et al., Sevoflurane ameliorates doxorubicin-induced myocardial injury
5. Sahu BD, Kumar JM, Kuncha M, et al. Baicalein alleviates dox-
orubicin-induced cardiotoxicity via suppression of myocardial 
oxidative stress and apoptosis in mice. Life Sci. 2016; 144: 8–18, 
doi: 10.1016/j.lfs.2015.11.018, indexed in Pubmed: 26606860.
6. Bartlett JJ, Trivedi PC, Yeung P, et al. Doxorubicin impairs cardio-
myocyte viability by suppressing transcription factor EB expres-
sion and disrupting autophagy. Biochem J. 2016; 473(21): 3769–
3789, doi: 10.1042/BCJ20160385, indexed in Pubmed: 27487838.
7. Li S, Liu C, Gu L, et al. Autophagy protects cardiomyocytes from 
the myocardial ischaemia-reperfusion injury through the clear-
ance of CLP36. Open Biol. 2016; 6(8), doi: 10.1098/rsob.160177, 
indexed in Pubmed: 27512143.
8. Xia Q, Zheng Yi, Jiang W, et al. Valproic acid induces autophagy 
by suppressing the Akt/mTOR pathway in human prostate 
cancer cells. Oncol Lett. 2016; 12(3): 1826–1832, doi: 10.3892/
ol.2016.4880, indexed in Pubmed: 27588130.
9. Ma R, Wang X, Peng P, et al. a-Lipoic acid inhibits sevoflurane-in-
duced neuronal apoptosis through PI3K/Akt signalling pathway. 
Cell Biochem Funct. 2016; 34(1): 42–47, doi: 10.1002/cbf.3163, 
indexed in Pubmed: 26781804.
10. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-
mTOR complex integrity and regulates Akt phosphorylation and 
substrate specificity. Cell. 2006; 127(1): 125–137, doi: 10.1016/j.
cell.2006.08.033, indexed in Pubmed: 16962653.
11. Dimmeler S, Assmus B, Hermann C, et al. Fluid shear stress stim-
ulates phosphorylation of Akt in human endothelial cells: involve-
ment in suppression of apoptosis. Circ Res. 1998; 83(3): 334–341, 
doi: 10.1161/01.res.83.3.334, indexed in Pubmed: 9710127.
12. Altomare DA, Wang HQ, Skele KL, et al. AKT and mTOR phos-
phorylation is frequently detected in ovarian cancer and can 
be targeted to disrupt ovarian tumor cell growth. Oncogene. 
2004; 23(34): 5853–5857, doi: 10.1038/sj.onc.1207721, indexed 
in Pubmed: 15208673.
13. Kim K, Park C, Kwon D, et al. Silicon nanowire biosensors 
for detection of cardiac troponin I (cTnI) with high sensitiv-
ity. Biosens Bioelectron. 2016; 77: 695–701, doi:  10.1016/j.
bios.2015.10.008, indexed in Pubmed: 26496224.
14. Romano MM, Pazin-Filho A, O’Connel JL, et al. Early detection 
of doxorubicin myocardial injury by ultrasonic tissue charac-
terization in an experimental animal model. Cardiovasc Ultra-
sound. 2012; 10: 40, doi: 10.1186/1476-7120-10-40, indexed in 
Pubmed: 23046747.
15. Ren D, Zhu Q, Li J, et al. Overexpression of angiopoietin-1 reduc-
es doxorubicin-induced apoptosis in cardiomyocytes. J Biomed 
Res. 2012; 26(6): 432–438, doi:  10.7555/JBR.26.20120006, in-
dexed in Pubmed: 23554782.
16. Conzen PF, Vollmar B, Habazettl H, et al. Systemic and regional 
hemodynamics of isoflurane and sevoflurane in rats. Anesth 
Analg. 1992; 74(1): 79–88, doi:  10.1213/00000539-199201000-
00014, indexed in Pubmed: 1734802.
17. Kim DE, Kim B, Shin HS, et al. The protective effect of hispi-
din against hydrogen peroxide-induced apoptosis in H9c2 car-
diomyoblast cells through Akt/GSK-3b and ERK1/2 signaling 
pathway. Exp Cell Res. 2014; 327(2): 264–275, doi:  10.1016/j.
yexcr.2014.07.037, indexed in Pubmed: 25128810.
18. Kang C, Avery L. To be or not to be, the level of autophagy is 
the question: dual roles of autophagy in the survival response to 
starvation. Autophagy. 2008; 4(1): 82–84, doi: 10.4161/auto.5154, 
indexed in Pubmed: 17952023.
19. Xu X, Chen K, Kobayashi S, et al. Resveratrol attenuates 
doxorubicin-induced cardiomyocyte death via inhibition of p70 
S6 kinase 1-mediated autophagy. J Pharmacol Exp Ther. 2012; 
341(1): 183–195, doi:  10.1124/jpet.111.189589, indexed in 
Pubmed: 22209892.
20. Jung CH, Ro SH, Cao J, et al. mTOR regulation of autopha-
gy. FEBS Lett. 2010; 584(7): 1287–1295, doi:  10.1016/j.febs-
let.2010.01.017, indexed in Pubmed: 20083114.
21. Papinski D, Kraft C. Regulation of Autophagy By Signaling 
Through the Atg1/ULK1 Complex. J Mol Biol. 2016; 428(9 
Pt A): 1725–1741, doi:  10.1016/j.jmb.2016.03.030, indexed in 
Pubmed: 27059781.
22. Ceyhan D, Tanrıverdi B, Bilir A. Comparison of the effects of 
sevoflurane and isoflurane on myocardial protection in coronary 
bypass surgery. Anadolu Kardiyol Derg. 2011; 11(3): 257–262, 
doi: 10.5152/akd.2011.059, indexed in Pubmed: 21466991.
23. Wang Y, Zuo M. Nicotinamide improves sevoflurane-induced cog-
nitive impairment through suppression of inflammation and anti-
apoptosis in rat. Int J Clin Exp Med. 2015; 8(11): 20079–20085, 
indexed in Pubmed: 26884920.
24. Inamura Y, Miyamae M, Sugioka S, et al. Sevoflurane postcondi-
tioning prevents activation of caspase 3 and 9 through antiapop-
totic signaling after myocardial ischemia-reperfusion. J Anesth. 
2010; 24(2): 215–224, doi: 10.1007/s00540-010-0877-6, indexed 
in Pubmed: 20177944.
25. Zhang J, Wang C, Yu S, et al. Sevoflurane postconditioning pro-
tects rat hearts against ischemia-reperfusion injury via the ac-
tivation of PI3K/AKT/mTOR signaling. Sci Rep. 2014; 4: 7317, 
doi: 10.1038/srep07317, indexed in Pubmed: 25471136.
418 www.cardiologyjournal.org
Cardiology Journal 2017, Vol. 24, No. 4
